新闻

Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review

9 月 3, 2024

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for pridopidine as a treatment for Huntington’s disease (HD). An MAA

阅读更多 "

Chronicle of a Relentless Quest: The Making of a Foundation

8 月 1, 2024

I belong to the third generation of a family affected by Huntington’s Disease, but it wasn’t until 2024, thanks to the tireless efforts of my second father, F. Cook, that we were able to confirm how the disease entered the family. My maternal great-grandfather, a Frenchman named Charles Novel-Catin (1883-1936),

阅读更多 "

IROS, Prilenia and International Huntington’s Disease Association collaborate on first-ever Huntington’s disease (HD) trial in the MENA region

7 月 11, 2024

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to plan the first-ever clinical trial for Huntington’s disease (HD) in the UAE and MENA region,

阅读更多 "

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for HD

7 月 9, 2024

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure. “We believe this is the first clinical trial of any investigational medicine

阅读更多 "

Wave 生命科学公司宣布 SELECT-HD 1b/2a 期试验取得积极成果，首次在临床上证明可降低亨廷顿氏症患者的等位基因选择性突变亨廷廷蛋白水平

6 月 25, 2024

今天，Wave Life Sciences 公司宣布了 SELECT-HD 的积极结果，这是我们评估研究疗法 WVE-003 的 1b/2a 期安慰剂对照试验。这些结果表明，WVE-003 能选择性地降低亨廷顿氏病患者体内有毒的突变型亨廷汀（mHTT）蛋白，并保留健康的野生型亨廷汀（wtHTT）蛋白。试验结果在分析中，比较了

阅读更多 "

中东和北非的最新情况

6 月 3, 2024

在上个月于阿布扎比举行的中东和北非罕见病大会上，IHA 主席斯文-奥拉夫-奥尔森（Svein Olaf Olsen）就亨廷顿氏病发表了主旨演讲。他谈到了在该地区建立神经退行性疾病卓越中心和促进临床研究的迫切需要。这与该地区的意图完全一致

阅读更多 "

Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review

9 月 3, 2024

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for pridopidine as a treatment for Huntington’s disease (HD). An MAA

阅读更多 "

Chronicle of a Relentless Quest: The Making of a Foundation

8 月 1, 2024

I belong to the third generation of a family affected by Huntington’s Disease, but it wasn’t until 2024, thanks to the tireless efforts of my second father, F. Cook, that we were able to confirm how the disease entered the family. My maternal great-grandfather, a Frenchman named Charles Novel-Catin (1883-1936),

阅读更多 "

IROS, Prilenia and International Huntington’s Disease Association collaborate on first-ever Huntington’s disease (HD) trial in the MENA region

7 月 11, 2024

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to plan the first-ever clinical trial for Huntington’s disease (HD) in the UAE and MENA region,

阅读更多 "

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for HD

7 月 9, 2024

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure. “We believe this is the first clinical trial of any investigational medicine

阅读更多 "

Wave 生命科学公司宣布 SELECT-HD 1b/2a 期试验取得积极成果，首次在临床上证明可降低亨廷顿氏症患者的等位基因选择性突变亨廷廷蛋白水平

6 月 25, 2024

今天，Wave Life Sciences 公司宣布了 SELECT-HD 的积极结果，这是我们评估研究疗法 WVE-003 的 1b/2a 期安慰剂对照试验。这些结果表明，WVE-003 能选择性地降低亨廷顿氏病患者体内有毒的突变型亨廷汀（mHTT）蛋白，并保留健康的野生型亨廷汀（wtHTT）蛋白。试验结果在分析中，比较了

阅读更多 "

中东和北非的最新情况

6 月 3, 2024

在上个月于阿布扎比举行的中东和北非罕见病大会上，IHA 主席斯文-奥拉夫-奥尔森（Svein Olaf Olsen）就亨廷顿氏病发表了主旨演讲。他谈到了在该地区建立神经退行性疾病卓越中心和促进临床研究的迫切需要。这与该地区的意图完全一致

阅读更多 "
zh_CNChinese
en_USEnglish arArabic bg_BGBulgarian cs_CZCzech da_DKDanish nl_NLDutch etEstonian fiFinnish fr_FRFrench de_DEGerman elGreek hu_HUHungarian id_IDIndonesian it_ITItalian jaJapanese lvLatvian lt_LTLithuanian pl_PLPolish pt_PTPortuguese ro_RORomanian ru_RURussian sk_SKSlovak sl_SISlovenian es_ESSpanish sv_SESwedish tr_TRTurkish ukUkrainian zh_CNChinese
跳至内容